Keystone Pharmaceuticals CS1001 Joint BLU-554 (CS3008) therapy approved for clinical trials in China

recently, Cornerstone Pharmaceuticals (Suzhou) LimitedCompany(http:// announcedthat its CS1001 joint BLU-554 (CS3008) therapy for the treatment of localized advanced or metastatic hepatocellular carcinoma (HCC) has been approved in China by the ClinicalTrial(http://the trial is a multicenter, open, multi-dose ib/II study designed to evaluate the safety, tolerance, pharmacokinetics and pharmacodynamics and anti-tumor efficacy of this combination therapy in the above-mentioned indicationsAbout CS1001
CS1001 is the anti-PD-L1 monoantigen developed by Keystone Pharmaceuticals, and it is also one of theof the(http:// of the three tumor immunotherapy skeletons (backbone)products of Cornerstone PharmaceuticalsCS1001 has now initiated clinical trials for the treatment of lung, stomach and other advanced malignanciesIn phase Ia trials, CS1001 showed good tolerance and anti-tumor activity, and partial remission was observed in multiple tumor strainsAbout THE BLU-554
BLU-554 is a powerful, highly selective FGFR4 inhibitor developed by Blueprint Medicines ("Blueprint"), a partner in Keystone Pharmaceuticalsan ongoing Phase I trial of advanced hepatocellular carcinoma with abnormal signaling pathways in FGF19-FGFR4 has published data showing that BLU-554 monodotherapy for advanced hepatocellular carcinoma has general good tolerance and shows encouraging anti-tumor activity the U.S FDA (http:// granted BLU-554 an orphan drug for hepatocellular carcinoma 　　In June 2018, Keystone Pharmaceuticals entered into an exclusive partnership and licensing agreement with Blueprint to acquire the rights to develop and commercialize in Greater China three candidate drug (http:// , including the BLU-554 Blueprint reserves the right to develop and commercialize the three drug candidates in other parts of the world